Physician profile

David Shiu

Pulmonary Disease · Middletown, NY

NPI 1649546458

$8,401.52

in general payments reported to CMS, 2019-2025

48 companies · $1,933 in 2025

The $1,933 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,399.42
Travel and Lodging$429.01
Education$277.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $2,625.40 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Astrazeneca Pharmaceuticals LP $1,699.26 2021-2025 Breztri, Tezspire, Airsupra
Intuitive Surgical, INC. $446.00 2023 Da Vinci Surgical System
Boehringer Ingelheim Pharmaceuticals, INC. $387.28 2021-2025 Ofev
Philips North America LLC $291.40 2024-2025 Vest Therapy Und, (Ak6) Vest Therapy
Mylan Specialty L.P. $274.00 2022-2024 Yupelri
Grifols USA, LLC $269.81 2021-2025 Prolastin-C Liquid
Actelion Pharmaceuticals US, INC. $268.79 2023-2025 Opsumit, Uptravi
Mallinckrodt Hospital Products INC. $238.88 2020-2025 Acthar
Genzyme Corporation $233.33 2020-2025
Amgen INC. $184.43 2021-2025 Evenity, Repatha, Otezla
Viatris Specialty LLC $118.21 2025 Yupelri
Pfizer INC. $103.89 2019-2021
Sanofi-Aventis U.S. LLC $99.99 2025
Inspire Medical Systems, INC. $86.86 2024-2025 Inspire
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Harmony Biosciences LLC $85.24 2021-2023 Wakix
Pulmonx Corporation $81.80 2020
Insmed, INC. $68.65 2020-2025 Arikayce
Takeda Pharmaceuticals U.S.A., INC. $61.78 2021-2025 Aralast, Glassia
Electromed, INC. $57.84 2022-2024 Smartvest
Merck Sharp & Dohme LLC $56.70 2022-2024 Capvaxive
Verona Pharma, INC. $52.41 2025 Ohtuvayre
Xeris Pharmaceuticals, INC. $50.72 2023-2025 Gvoke Hypopen, Recorlev
Regeneron Healthcare Solutions, INC. $42.98 2022-2024 Dupixent
Sunovion Pharmaceuticals INC. $35.81 2019
Alexion Pharmaceuticals, INC. $35.69 2023-2025 Strensiq
Vifor Pharma, INC. $33.19 2025 Zemaira
Ani Pharmaceuticals, INC. $30.46 2024-2025 Purified Cortrophin Gel
Medtronic, INC. $29.25 2022
Teva Pharmaceuticals USA, INC. $27.71 2021-2022
Abbott Laboratories $27.22 2021-2022
Aurinia Pharma U.S., INC. $24.36 2025 Lupkynis
Mallinckrodt Enterprises LLC $23.83 2019
Medtronic Minimed, INC. $22.50 2019
Lilly USA, LLC $20.43 2025 Zepbound
Kyowa Kirin, INC. $18.92 2025
Janssen Biotech, INC. $17.97 2024 Tremfya
Novo Nordisk INC $17.08 2021
Ibsa Pharma INC. $16.74 2025 Flector, Licart, Tirosint
United Therapeutics Corporation $16.51 2024 Tyvaso
Fisher & Paykel Healthcare INC $16.49 2025 Fisher & Paykel Healthcare
Recordati_rare_diseases_inc. $16.35 2024 Signifor Lar, Isturisa
Avadel Cns Pharmaceuticals, LLC $16.02 2024 Lumryz
Mannkind Corporation $15.95 2024
Shire North American Group INC $14.33 2019
Amarin Pharma, INC. $13.96 2021
Genentech USA, INC. $12.64 2022
Nabriva Therapeutics, Plc $12.46 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Shiu

$8,401.52

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,933 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/1386798/david-shiu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.